贝达喹啉治疗耐多药和利福平耐药结核病的现状与展望  

Current status and perspectives of bedaquiline in the treatment of multidrug/rifampicin-resistant tuberculosis

作　　者：时正雨 邹莉萍 李秀 黄涛 吴桂辉 唐神结[2] Shi Zhengyu;Zou Liping;Li Xiu;Huang Tao;Wu Guihui;Tang Shenjie(Division of Tuberculosis,Chengdu Public Health Clinical Medical Center,Chengdu 610000,China;Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149,China)

机构地区：[1]成都市公共卫生临床医疗中心结核科,成都610000 [2]首都医科大学附属北京胸科医院、北京市结核病胸部肿瘤研究所,北京101149

出　　处：《中华结核和呼吸杂志》2023年第3期211-216,共6页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：四川省医学科研课题计划(S18027);成都市科学技术局成都市技术创新研发项目(2022-YF05-02139-SN)。

摘　　要：耐多药和利福平耐药结核病的流行情况依然严峻,贝达喹啉是治疗该病的核心药物之一,可以提高治疗成功率和降低病死率。该药在组成全口服短程治疗方案、与其他抗结核新药联合使用、特殊人群中的使用等方面具有很好的应用前景,但目前仍处于探索阶段。本专题探讨贝达喹啉的临床应用现状和展望,旨在为医务工作者提供借鉴。The prevalence of multidrug/rifampicin-resistant tuberculosis is still a major problem in China and around the world.Bedaquiline is one of the key drugs in the treatment of multidrug/rifampicin-resistant tuberculosis,with the potential to improve outcomes and reduce mortality.Bedaquiline has a promising future in oral short-course treatment regimens,in combination with other novel anti-tuberculosis drugs,and in a special patient population.In this feature article,we discussed the current status and future prospects of the clinical application of bedaquiline in order to provide references for physicians.

关 键 词：抗结核新药 耐多药 临床应用现状 核心药物 特殊人群 利福平耐药结核病 专题探讨 贝达喹啉 

分 类 号：R52[医药卫生—内科学]